Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nintedanib - Boehringer Ingelheim

Drug Profile

Nintedanib - Boehringer Ingelheim

Alternative Names: BIBF-1120; Intedanib; Ofev; Vargatef

Latest Information Update: 19 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Carolinas HealthCare System; Duke University; European Organisation for Research and Treatment of Cancer; Lurie Cancer Center; M. D. Anderson Cancer Center; National Cancer Institute (USA); Northwestern University; Roswell Park Cancer Institute; University of Alabama at Birmingham; University of Texas Southwestern Medical Center
  • Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Idiopathic pulmonary fibrosis; Systemic scleroderma; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Non-small cell lung cancer
  • Phase III Colorectal cancer; Interstitial lung diseases; Mesothelioma; Ovarian cancer; Systemic scleroderma
  • Phase II Bladder cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Inflammatory breast cancer; Liver cancer; Peritoneal cancer; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I/II Pancreatic cancer
  • Phase I Acute myeloid leukaemia; Solid tumours
  • No development reported Multiple myeloma
  • Discontinued Prostate cancer

Most Recent Events

  • 30 Jan 2019 Boehringer Ingelheim plans a phase III trial for Interstitial lung disease (Treatment-experienced) in April 2019 (NCT03820726)
  • 14 Nov 2018 Phase-I clinical trials in Acute myeloid leukaemia (Refractory metastatic disease, Combination therapy, Second-line therapy or greater, Newly diagnosed) in USA (PO) (NCT03513484)
  • 08 Nov 2018 Boehringer Ingelheim initiates enrolment in a phase I trial for Systemic scleroderma in Germany (NCT03675581)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top